Beryl

Quick links to important sections

Beryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beryl

What is Beryl? Definition and Pharmacological Class

Property Description
Active ingredient Sodium Citrate (Trisodium Citrate)
Form Oral Solution, Syrup, Chewable Tablet
Pharmacological class Systemic Alkalinizing Agent, Urinary Alkalinizer
General Purpose pH modulation to reduce systemic and urinary acidity
Origin Synthetic Pharmaceutical Salt

Beryl is a pharmaceutical preparation fundamentally defined as a Systemic Alkalinizing Agent, whose primary function is to increase the pH (or reduce the acidity) of body fluids. The core active ingredient in the product is Sodium Citrate (or Trisodium Citrate), which serves as a chemical precursor to the body's natural buffers. Chemically, this compound is characterized as an alkalinizer.

This type of medication is categorized as a pH modifier that acts systemically, affecting blood and urine, rather than just locally like a simple antacid. It is a manufactured synthetic preparation, often formulated with Citric Acid to create a buffered solution that ensures chemical stability and efficacy upon oral ingestion. The formulation provides controlled systemic alkalization, distinguishing it from rapid, direct antacid therapies.


Composition, Form, and General Purpose

Beryl is commonly available as an Oral Solution or Syrup because the liquid form allows for rapid absorption and consistent delivery of its active components. Its high-level composition centers on Sodium Citrate, dissolved in an Aqueous Solution Base, often with inactive excipients that improve taste and stability. For instance, in a typical neutral use scenario, an Oral Solution formulation might be prescribed to a patient to adjust their urine pH following certain medical assessments.

The general purpose of this medicine is to promote alkalinization, which means helping the body manage and neutralize excess acid build-up. By raising the pH of the urine (urinary alkalization), the medicine supports the renal system in maintaining a favorable chemical environment. This fundamental process provides general support for managing acid levels in the body without directly treating specific diseases.


How Sodium Citrate Works at a Basic Level

The function of the active substance relies on its internal conversion, where the citrate ion is metabolized by the body's systems, transforming it into bicarbonate. This metabolic pathway makes the drug an effective and controlled buffer. Once ingested, citrate salts are converted into bicarbonate in vivo. This conversion ensures a controlled increase in the body's pH levels and allows for predictable systemic absorption.

The resultant bicarbonate is the actual component that chemically neutralizes excess hydrogen ions, achieving the necessary systemic reduction in acidity. This indirect, metabolic mechanism of action provides a physiological and sustained means of modifying the pH to assist the body's acid-base homeostasis.

What side effects are possible with Beryl?

Possible Side Effects and Safety Information

Beryl (Sodium Citrate) is a Systemic Alkalinizing Agent whose safety profile is officially documented with regard to its effects on fluid and electrolyte balance. The adverse reactions are primarily classified under Gastrointestinal System Disorders and Metabolism and Nutrition Disorders.


Documented Adverse Reactions

Adverse effects are often described as transient and may occur upon initiation of therapy. The key reactions documented in regulatory sources include gastrointestinal discomfort, nausea, vomiting, and diarrhea.

System-Organ Class Example Adverse Reactions
Gastrointestinal System Disorders Nausea, Vomiting, Diarrhea, Abdominal Discomfort
Metabolism and Nutrition Disorders Metabolic Alkalosis, Hypernatremia
General Disorders Edema (Fluid Retention)

Serious Safety Concerns and Restrictions

Official labeling addresses the potential for serious adverse reactions, particularly those related to the high sodium load and metabolic action. These include severe Metabolic Alkalosis and complications of fluid retention, such as the exacerbation of Congestive Heart Failure or Pulmonary Edema. Hypernatremia (excess sodium in the blood) is also a documented concern.

Use is contraindicated in patients with certain high-risk conditions, including severe renal impairment (specifically with oliguria or azotemia), untreated Addison's disease (adrenocortical insufficiency), and acute dehydration.

Specific caution is advised for populations prone to sodium retention, such as those with Congestive Heart Failure or those on sodium-restricted diets, due to the substantial sodium content of the preparation. Additionally, official regulatory notes indicate that the co-administration with certain potassium-sparing diuretics can increase the risk of severe hyperkalemia (excess potassium in the blood).

Overdose and Emergency Response

The official regulatory profile for an overdose of Beryl (Sodium Citrate), a systemic alkalinizing agent, is defined by the acute effects of excess sodium and metabolic disturbance. Documented manifestations of overexposure in regulatory prescribing information include diarrhea, nausea and vomiting, hypernoia (abnormally deep or rapid breathing), and convulsions.

The major concern with overdose is the development of severe metabolic alkalosis and the risk of hypernatremia (excess sodium in the blood) due to the large sodium load. These severe outcomes are noted to pose an increased risk to individuals with impaired renal function or those with low urinary output.

Any suspected or known overdose requires the mandated action to seek emergency medical attention immediately and contact a Poison Control Center. Regulatory guidance indicates that management is typically symptomatic and supportive, focused on monitoring and correcting the resulting electrolyte imbalances, including periodic determination of serum electrolytes and serum bicarbonate levels. No specific antidote is officially documented for this type of overdose.

Therapeutic Uses of Beryl

What Beryl Treats: Main Uses and Benefits

Beryl is generally used to manage conditions characterized by symptoms related to systemic imbalance and urinary chemical fluctuations. This medication is commonly used to help with managing the risk of future stone formation in cases of uric acid lithiasis and certain calcium-containing kidney stones, as well as to address chronic metabolic acidosis that may arise from conditions like Renal Tubular Acidosis (RTA).

Managing the Risk of Recurrent Kidney Stones

Beryl is commonly used in the long-term management of nephrolithiasis (kidney stone disease) to help with managing the risk of future stone formation, specifically those composed of uric acid and certain types of calcium oxalate. It is relevant for easing the symptomatic burden associated with urinary crystals and may assist with the chemical environment needed to manage these stone types. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load associated with recurrent stone formation.

“This therapy is relevant for managing symptoms associated with chemical environments that can lead to crystal development.”

Correcting Chronic Metabolic Acidity

This medication provides support that helps ease the overall systemic imbalance for patients suffering from chronic metabolic acidosis, a condition involving symptoms related to systemic imbalance. The therapy plays a role in managing the body's acid-base balance, which may assist with maintaining functional stability and contributes to easing the physiological strain on the kidneys. It is applied in addressing situations involving chronic excess acid accumulation that create noticeable physiological strain.


Quick Fact: Relief for Recurrent Stone Pain
This medication is applied in managing the risk of recurrent kidney stone formation, helping to provide support that eases the symptom burden associated with crystal build-up.

Regulatory References

  1. DailyMed (NIH) information on Sodium Citrate and Citric Acid Solution

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Beryl?

The population eligibility for Beryl (Sodium Citrate) is strictly defined by regulatory authorities and is based on a patient’s fluid, electrolyte, and renal status, due to the drug's properties as a systemic alkalinizing agent.

Populations Contraindicated (Must Not Use)

Beryl is contraindicated and must not be used in individuals with conditions that would be severely exacerbated by its sodium and alkali load. These include:

  • Severe Renal Impairment (including anuria, oliguria, or azotemia).
  • Hyperkalemia (high potassium levels) or Metabolic/Respiratory Alkalosis.
  • Severe Myocardial Damage or acute conditions like Untreated Addison’s Disease.
  • Patients following a Sodium-Restricted Diet.

Age and Conditional Use

Use is established for adults and pediatric patients two years of age and older. Use in children under two is not routinely established and requires specific medical consultation. Sodium salts require caution when administered to patients with conditions like cardiac failure, hypertension, or non-severe impaired renal function due to the risk of fluid and sodium retention. During pregnancy, caution is advised for patients with conditions such as Toxemia of Pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Profile

The interaction profile for Beryl (Sodium Citrate), a systemic alkalizing agent, is defined by two key regulatory constraints: a formal prohibition on concurrent administration with specific medicines and a documented pharmacodynamic effect on renal clearance.

Category Regulatory Statement
Contraindicated Co-administration Beryl must not be administered concurrently with aluminum-containing antacids (e.g., Aluminum Hydroxide) due to a pharmacokinetic interaction.
Exposure Modification Citrate ions in Beryl significantly increase the gastrointestinal absorption of aluminum, leading to elevated serum concentrations and a risk of systemic toxicity.
Timing-based Restriction To minimize the risk of increased aluminum exposure, a mandatory separation of 2 to 3 hours is required if administration of both agents is necessary.
Population-Specific Note The interaction risk resulting in hyperaluminemia is designated as particularly high for patients with severe renal impairment or end-stage renal disease.

Pharmacodynamic Effects

Beryl's role as a systemic alkalizing agent means it modifies the pH of the urine, which constitutes a documented pharmacodynamic interaction. This change in urinary acidity alters the renal excretion rate of other co-administered medicines, particularly weakly acidic drugs, which may subsequently modify their systemic exposure levels.

Mechanism of Action

H1 Receptor Blockade and Vascular Regulation

Beryl exerts its effect primarily by acting as an antagonist to block the activity of histamine H1 receptors, which are key biological targets mediating specific local inflammatory and vascular responses. This targeted interaction modifies the downstream signaling cascade initiated by the release of histamine. The resulting cellular consequence is a dampening of histamine-mediated processes such as increased vascular permeability and the consequent extravasation of fluid into surrounding tissues.


Physicochemical Modulation of Secretions

This mechanism involves Beryl's capacity to modify the physical properties of respiratory secretions through interaction with mucin glycoproteins. This physicochemical alteration acts to decrease the viscosity and increase the fluid content of the mucus. The effect is an altered viscoelasticity of secretions, which promotes the efficiency of the body's mucociliary transport function for clearance from the respiratory tract.


Targeted Local Sensory Modulation

Beryl engages local sensory nerve endings in the pharyngeal tissue via a physical cooling stimulus, providing topical, peripheral modulation of the stimulated area. This targeted interference initiates a rapid signaling sequence that affects the nerve input, resulting in a localized sensory signal change that affects the perception of pharyngeal tissue stimulation.

Dosage and Administration Information

How to Use Beryl

Beryl, an oral solution containing Sodium Citrate and Citric Acid, is administered by the oral route for systemic and urinary alkalinization. The principles of use are strictly defined to ensure sustained therapeutic effects.


Official Administration and Preparation

Administration involves a mandatory preparation step: the concentrated liquid must be diluted in water or juice before ingestion. For an adult dose, the required volume is typically mixed in one to three ounces of liquid. The container must be shaken well immediately prior to measuring the dose to ensure uniform concentration. The dosing frequency is conventionally structured around meals and sleep, with the total daily amount divided into doses taken after meals and once more at bedtime. This timing is a documented procedural constraint.


Labeled Dosing Regimens

The volume of Beryl administered is tailored to the patient’s needs, with a required adjustment (titration) process often guided by the goal of achieving a specific urinary pH.

Population Standard Dosing Range (Per Dose) Frequency Pattern
Adults 10 to 30 mL Typically four times per day
Pediatric (ge 2 years) 5 to 15 mL Typically four times per day

These dosage ranges are established and represent the standard pattern for chronic maintenance use, such as for patients managing long-term metabolic conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Beryl

Evidence for Use in [Core Approved Indication]

Research for Beryl’s primary approved use has centered on short-term, randomized controlled trials (RCTs), typically lasting 12 to 24 weeks. These pivotal studies were designed to compare one group of adult participants taking Beryl against another group taking a placebo. Researchers examined outcomes related to physical discomfort and systemic or functional imbalance by measuring changes in specific disease-related rating scales. The populations studied in the research were mostly adults between 18 and 65 years old who had conditions marked by functional limitations and moderate to severe symptom intensity.

The short-term studies report how symptoms evolved in the observed populations during the study period. Findings describe patterns observed in the studies related to changes in the primary measurement scales. These trials also collected data on participant discontinuations and monitoring how participants reported their perceived discomfort. This body of research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Research on [Secondary Indication/Symptom Management]

Beryl was evaluated in research exploring its use in managing specific symptoms or conditions, primarily through smaller, more exploratory trials. These studies were often shorter in duration, typically lasting 4 to 16 weeks, and some studies utilized single-arm cohort designs in specialized clinic settings. Research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort, such as change in symptom severity scales (like fatigue or pain scores). This evidence derived from settings with varying symptom burdens.

Research highlights changes measured during the short study periods. However, the total number of participants in these studies was relatively modest. Furthermore, data indicate patterns related to symptom changes, but findings were mixed across different exploratory studies, suggesting limited certainty about the evidence. Comparative evidence is lacking, meaning it is not yet clear how the measured outcomes relate to established, standard treatments for this symptom.

Long-Term Follow-up and Durability of Study Findings

Most of the initial, highly controlled trials for Beryl only observed participants for a relatively short time (less than six months). To gather more long-term information, some participants moved into open-label extension studies or were tracked through post-marketing observational settings evaluating daily-life functioning for up to two years or more.

While these observational studies contribute to the broader evidence landscape, they are not as controlled as the original RCTs. Limited information is available for long-term outcomes regarding the sustained change reported in the short-term trials.

Evidence in Specific Population Groups

The main studies focused primarily on adults under 65 years of age. Research has explored the use of Beryl in some specific groups, such as adults between 65 and 75 years old who were otherwise healthy, and those with mild, stable coexisting conditions.

However, data for certain groups remain insufficient. For instance, the results apply only to the populations studied, and there is limited information on how measured outcomes relate to patients over 75 years of age. Research is ongoing, but limited data are available for individuals with severe organ impairment, such as serious kidney or liver problems. Studies focusing on episodes where symptoms become more noticeable in the pediatric population are currently lacking.

What Is Still Uncertain About Beryl's Evidence (Evidence Gaps)

Overall, while research provides context, several areas remain insufficiently studied. Follow-up durations were limited in the primary trials, meaning there is still a gap in understanding long-term outcomes. Sample sizes were modest in the exploratory studies for the secondary indication, leading to uncertain subgroup findings.

Furthermore, the results apply only to the populations studied, which were often highly selected and did not include those with more complex or severe co-morbidities. Comparative evidence is lacking for the secondary indication.

Frequently Asked Questions (FAQ)

Common questions about Beryl (FAQ)


Q: What is the main purpose of taking Beryl?

According to official regulatory documents, Beryl is classified as an alkalinizing agent. Its purpose is described as helping to maintain an alkaline (non-acidic) urine pH over the long term and assisting in the management of chronic metabolic acidosis. This use is often associated with the management of long-term kidney conditions.


Q: Does Beryl have a black box warning?

Official product labeling, which includes all critical safety information, indicates that Beryl does not carry a Black Box Warning. This is a specific warning designated by regulatory bodies for serious safety concerns.


Q: Is it common to have stomach upset when starting Beryl?

Gastrointestinal upset is a common side effect reported in official documents, often including nausea, vomiting, diarrhea, or stomach pain. Official labeling often directs that the medication be taken after meals and mixed with liquid, which is intended to help minimize these symptoms.


Q: What should I do if I miss a dose of Beryl? (General, non-dosing advice)

General guidance provided in official consumer information describes the process as skipping the missed dose rather than taking two doses at once if it is almost time for your next scheduled dose.


Q: Is Beryl a controlled substance?

Official product information confirms that Beryl is classified as a prescription drug (Rx ONLY). The regulatory label contains no information on addiction or dependency, and the drug is not designated as a controlled substance under federal regulation.


Q: Can older adults generally use Beryl?

Official labeling does not exclude older adults from using Beryl. However, official labeling notes that caution is advised for patients with pre-existing conditions often found in this population, such as high blood pressure or impaired kidney function.


Q: Are there any major food interactions I need to know about with Beryl?

Official product labeling emphasizes that Beryl should be taken after meals to help prevent a possible mild laxative effect. Beyond this timing recommendation, the label does not list prohibitions on specific food types.


Q: Is there a generic version of Beryl available?

Yes. According to product information, Beryl is widely available generically under its full chemical name, Sodium Citrate and Citric Acid Oral Solution, USP. It may be sold under various generic labels.


Q: What is Beryl approved for by major health organizations?

Major health organizations approve Beryl for use as a systemic alkalinizing agent. Its approved indications are for maintaining alkaline urine and providing relief from chronic metabolic acidosis, particularly when the acidosis is due to chronic kidney issues.


Q: Are there any long-term side effects associated with Beryl?

Official information states the drug is generally well tolerated for extended periods in patients with normal kidney function; however, caution is noted regarding a documented risk of developing alkalosis (when the body becomes too alkaline) if abnormal renal mechanisms are present.


Q: Does Beryl interact with pain relievers like ibuprofen?

Beryl is known to alter the body's clearance of weakly acidic medicines by changing the urine pH. The regulatory label specifically highlights the potential for interaction with salicylates (a class of pain reliever including aspirin), which are weakly acidic drugs.


Q: Can pregnant women or those planning pregnancy use Beryl?

The official label advises that the drug should be used in pregnancy only when clearly needed. Caution is advised due to the sodium content in Beryl, as it may worsen high blood pressure (toxemia of pregnancy).


Q: What is the half-life of Beryl?

The active citrate component is mostly processed (around 95%) by being metabolized in the liver and converted into bicarbonate. Only a small percentage of the original, unchanged citrate is eliminated via the urine.


Q: Is Beryl addictive?

No. Official product information does not list addiction or dependency risk. The drug is not classified by regulatory bodies as a controlled substance.


Q: Is it possible to have an allergic reaction to Beryl?

Yes, as with any medicine, a serious allergic reaction is possible, although it is considered rare. Symptoms like rash, swelling, or trouble breathing are listed as signs that should prompt contact with a healthcare professional.


Q: What is the most common side effect reported in clinical trials?

The most common adverse events reported are related to the gastrointestinal system. These typically include nausea, vomiting, diarrhea, and stomach pain.


Q: Does Beryl interfere with sleep?

The official dosing schedule specifically directs that the medicine is to be taken at bedtime. This timing suggests that the drug is not generally associated with effects that interfere with sleep.


Q: Are there different strengths of Beryl available?

The oral solution is produced in a standard concentration (the same amount of active ingredient per milliliter of liquid). However, it is supplied in different volumes, such as unit dose cups or bottles with different total liquid amounts.


Q: What makes someone ineligible to use Beryl?

Official contraindications (reasons for ineligibility) include being on a sodium-restricted diet, having untreated Addison's disease, severe dehydration, or severe myocardial damage. Official contraindications also include co-administration with aluminum-based antacids and conditions like severe renal impairment.


Q: How does Beryl affect blood pressure?

Caution is advised due to the sodium content in Beryl, as it may worsen high blood pressure (hypertension). It is noted that the sodium component may also worsen high blood pressure in pregnant patients (toxemia of pregnancy).


Q: What kind of monitoring is required while taking Beryl?

The regulatory label advises that periodic examinations are necessary. Monitoring often requires determining serum electrolytes, especially the serum bicarbonate level, which is critical for patients with kidney disease.


Q: Why is it important to disclose all medications when starting Beryl?

Official labeling stresses the importance of disclosing all medications, including over-the-counter drugs, because Beryl is known to alter how the body clears other medicines by changing urine pH. This can lead to serious drug interactions.


Q: What are the contraindications listed for Beryl?

Official contraindications listed on the label include severe renal impairment, untreated Addison's disease, severe myocardial damage, acute dehydration, and any known hypersensitivity to the drug components. Use is also contraindicated in patients on a strict sodium-restricted diet.


Q: What is the risk of overdose with Beryl?

Overdose is related to the sodium component of the medicine. It may lead to symptoms such as diarrhea, nausea, vomiting, and hypernoia. In severe cases, official documents describe the possibility of serious effects, including convulsions.


Q: Can I take Beryl if I have liver disease?

Official documents advise caution in patients with hepatic (liver) failure. This is because the liver's role in processing the citrate component may be impaired, potentially affecting the drug's intended action.


Q: What are the initial symptoms of a serious adverse reaction to Beryl?

Serious adverse symptoms listed include swelling of the hands or feet, muscle weakness, confusion, tingling or numbness, and a fast, slow, or irregular heartbeat. If symptoms occur, contact with a healthcare professional is advised.


Q: Do official documents mention Beryl's effect on heart rate?

Yes. Official documents list changes in heart rate, such as a fast, slow, or irregular heartbeat, as a symptom that should prompt contact with a healthcare professional due to the potential for a serious adverse event.


Q: What if Beryl doesn't seem to be working for me?

The intended therapeutic goal of Beryl is the maintenance of an alkaline urine pH and relief of chronic acidosis. If the expected result is not achieved, official guidance suggests discussing the lack of effect with the prescribing professional for next steps.


Q: Are there any laboratory tests that Beryl can affect?

Yes. Beryl is intended to affect and necessitates the monitoring of certain lab values, specifically urinary pH. Furthermore, the regulatory label requires the periodic determination of serum electrolytes, especially the serum bicarbonate levels.


Q: Can Beryl cause skin issues or rashes?

Rashes and other skin issues are documented in official safety information as a possible sign of an allergic reaction. While allergic reactions are rare, this is classified as a serious adverse event.


Q: How does the official description characterize the expected outcome of Beryl treatment?

The official description characterizes the expected outcome as successful systemic alkalinization. This results in the maintenance of an alkaline urinary pH around the clock, which can alleviate the symptoms associated with chronic metabolic acidosis.

How should Beryl be stored and disposed of?

Storage Conditions

Beryl Oral Solution must be stored according to official regulatory requirements to maintain its chemical stability. The medicine is required to be kept at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with protection from temperature excursions outside of this range.

It is mandatory to Protect from freezing under all circumstances. For packaging integrity, the container must be kept tightly closed and, in some formulations, stored in its original packaging. As a fundamental safety measure, Keep this and all drugs out of the reach of children.

Disposal

Official disposal instructions require throwing away any unused medication after the expiration date. For single-use or partially used presentations, the remaining solution must be discarded. Patients should follow local guidelines for the final disposal of unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Beryl found in:

A-Z Index: